0001104659-23-105925.txt : 20231002 0001104659-23-105925.hdr.sgml : 20231002 20231002163908 ACCESSION NUMBER: 0001104659-23-105925 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230928 FILED AS OF DATE: 20231002 DATE AS OF CHANGE: 20231002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fitzgerald Thomas A CENTRAL INDEX KEY: 0001854168 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40363 FILM NUMBER: 231300246 MAIL ADDRESS: STREET 1: C/O TRANSCODE THERAPEUTICS, INC. STREET 2: 6 LIBERTY SQUARE, #2382 CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 4 1 tm2327413d2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-09-28 0 0001829635 Transcode Therapeutics, Inc. RNAZ 0001854168 Fitzgerald Thomas A C/O TRANSCODE THERAPEUTICS, INC. 6 LIBERTY SQUARE, #2382 BOSTON MA 02109 1 1 0 0 Chief Financial Officer 0 Common Stock 2023-09-28 4 P 0 49350 0.51 A 56318 D Represents shares acquired pursuant to an underwritten public offering of common stock by the Issuer. Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023. /s/ Thomas A. Fitzgerald 2023-10-02